Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry

Brain Pathology

Volumn 22, Issue 1, 2012, Pages 26-31

  Sahm, Felix ^a,b   Capper, David ^a,b   Pusch, Stefan ^b   Balss, Jörg ^b   Koch, Arend ^d   Langhans, Claus Dieter ^c   Okun, Jürgen G ^c   Von Deimling, Andreas ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

2 hydroxyglutarate; FFPE; GC MS; glioma; IDH1; IDH2; stable isotope dilution

Indexed keywords

2 HYDROXYGLUTARIC ACID; FORMALDEHYDE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; PARAFFIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBEDDING; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GLIOMA; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS FRAGMENTOGRAPHY; MENINGIOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

BRAIN NEOPLASMS; FIXATIVES; FORMALDEHYDE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLIOMA; GLUTARATES; HUMANS; PARAFFIN; PARAFFIN EMBEDDING; TISSUE FIXATION;

EID: 83555174898     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00506.x     Document Type: Article

References (25)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
2. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al, (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
3. Brehmer S, Pusch S, Schmieder K, Von Deimling A, Hartmann C, (2010) Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathol Appl Neurobiol 37: 330-332.
4. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A, (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
5. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J, (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34: 1199-1204.
6. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, et al, (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254.
7. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al, (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
8. Dang L, Jin S, Su SM, (2010) IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16: 387-397.
9. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC, Reifenberger G, (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119: 501-507.
10. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al, (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
11. Hemerly JP, Bastos AU, Cerutti JM, (2010) Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 163: 747-755.
12. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN, (2010) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12: 487-492.
13. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP, (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347.
14. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al, (2009) Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355.
15. Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van der Knaap MS, et al, (2010) IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330: 336.
16. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, et al, (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20: 298-300.
17. Moroni I, Bugiani M, D'Incerti L, Maccagnano C, Rimoldi M, Bissola L, et al, (2004) L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology 62: 1882-1884. (Pubitemid 38661759)
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al, (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
19. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, Von Deimling A, (2010) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol (in press).
20. Rzem R, Veiga-da-Cunha M, Noel G, Goffette S, Nassogne MC, Tabarki B, et al, (2004) A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A 101: 16849-16854. (Pubitemid 39601327)
21. Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, et al, (2010) Immunohistochemical analysis of 1844 human epithelial and hematopoietic tumors and sarcomas for IDH1R132H mutation. Histopathology (in press).
22. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al, (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
23. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
24. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al, (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880.
25. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.